ClinicalTrials.gg
CompletedNCT00225433Updated Dec 3, 2015

Luteal Phase FSH in the IVF Poor Responder

A Phase 4 interventional study of follitropin beta and ganirelix acetate in Infertility, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to female participants aged 20 Years to 42 Years. Per ClinicalTrials.gov, last updated 2015-12-03.

Sponsored by University of Pennsylvania · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 42 Years
Sex
Female
01

Study summary

In vitro fertilization (IVF) is a common procedure used to assist couples who have difficulty conceiving a pregnancy. IVF is a process where oocytes (eggs) are retrieved from a woman's ovaries and fertilized with sperm in the laboratory. In order to maximize the number of oocytes that can be retrieved, a women undergoes ovarian stimulation with recombinant follicle stimulating hormone (FSH). Typically 6-20 oocytes are retrieved, but in some cases there is a limited response to the stimulation, producing a limited number of oocytes. This is called poor ovarian response.

This study is designed to objectively compare two treatment regimens currently advocated in clinical practice, but never compared directly. The purpose is to assess ovarian response to starting treatment at the end of the preceding cycle may increase the number of developing oocytes.

02

Conditions studied

  • Infertility

Browse trials for

Keywords

  • infertility
  • in vitro fertilization
03

In context

Infertility

2,540 studies on the registry are indexed under Infertility; 405 are open to participants now.

This study's enrollment of 20 is below the median of 120 across 1,722 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,664 studies on the registry; 236 are open to participants now.

Of its 156 completed or terminated interventional studies of FDA-regulated products, 107 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Infertile women planning to undergo IVF
  2. Poor ovarian response in most-recent previous IVF cycle within the past 18 months as defined by the following criteria:

    A) \<5 dominant follicles day of hCG, B) \<5 oocytes retrieved, or C) cancellation of a previous IVF cycle due to poor response to ovulation stimulation.

  3. Aged 20-42 (inclusive) at the time of randomization
  4. Presence of both ovaries
  5. Normal pap smear within past three years
  6. At least 45 days after the last IVF cycle
  7. Be willing and able to comply with the protocol for the duration of the study
  8. Have given written informed consent, prior to any study-related procedure, not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.

Exclusion criteria

Exclusion Criteria:

  1. Clinically significant systemic disease
  2. Current regular cigarette smoking by patient report
  3. Known to be positive for Human Immunodeficiency Virus
  4. Any medical condition which, in the judgment of the investigator and sponsor, may interfere with the absorption, distribution, metabolism or excretion of the medications used
  5. Abnormal, undiagnosed gynecological bleeding
  6. Known allergy or hypersensitivity to human gonadotropin preparations
  7. Simultaneous participation in another investigational drug or device trial
  8. Subject fails, in 2 separate menstrual cycle attempts, to have FSH ≤12.0 and an ultrasound exam within normal limits (per standard for IVF) at the Baseline Visit
  9. For subjects randomized to the Luteal Phase Regimen, failure to ovulate in 2 separate menstrual cycle attempts, as evidenced by ovulation predictor kit, progesterone level, and /or visualization of corpus luteum cyst on an ovary by ultrasound exam at the Luteal Visit
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    1

    Follitropin beta

    Drug: follitropin beta

  • Active comparator
    2

    Ganirelix acetate

    Drug: ganirelix acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Number of oocytes retrieved for IVF

    Time frame: One cycle

Secondary outcomes

  1. Number of follicles >10mm on day of human chorionic gonadotropin (hCG) administration;

    Time frame: 1 cycle

  2. Number of days of stimulation;

    Time frame: 1 cycle

  3. Estradiol level on the day of hCG administration;

    Time frame: 1 cycle

  4. Clinical pregnancy rate per transfer: defined as the presence of an intrauterine sac on transvaginal ultrasound;

    Time frame: 1 cycle

  5. Delivery rate per transfer;

    Time frame: 1 cycle

  6. Safety (incidence of ovarian torsion, severe risk of ovarian hyperstimulation syndrome, enlarging hemorrhagic cysts, and serious adverse events)

    Time frame: 1 cycle

07

Study locations

1 site
  • University of Pennsylvania Reproductive Research Unit
    Philadelphia, Pennsylvania 19104, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00225433
Responsible party
Sponsor
First posted
Sep 23, 2005
Start date
Sep 2005
Primary completion
Dec 2006
Completion
Jun 2008
Last update
Dec 3, 2015

Study contacts

Kurt T Barnhart, MD, MSCE
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Follitropin beta · Ganirelix

Start the discussion